share_log
  • Headlines
  • ORIC Pharmaceuticals Announced The Presentation Of A Poster Highlighting ORIC-114, A Brain Penetrant, Orally Bioavailable, Irreversible EGFR/HER2 Inhibitor, To Treat EGFR Exon 20 Insertions And Other Atypical Mutations

ORIC Pharmaceuticals Announced The Presentation Of A Poster Highlighting ORIC-114, A Brain Penetrant, Orally Bioavailable, Irreversible EGFR/HER2 Inhibitor, To Treat EGFR Exon 20 Insertions And Other Atypical Mutations

Benzinga ·  Oct 23 19:16
ORIC Pharmaceuticals Announced The Presentation Of A Poster Highlighting ORIC-114, A Brain Penetrant, Orally Bioavailable, Irreversible EGFR/HER2 Inhibitor, To Treat EGFR Exon 20 Insertions And Other Atypical Mutations
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated